Welcome to ProAxsis

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease, using its patented ProteaseTag® technology.

ProAxsis specialises in four key areas of business:-

 

 

 

 

 

 

     
     

News

ProAxsis abstracts at 2017 British Thoracic Society Winter Meeting
ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thorac...
ProAxsis provides update on commercialisation progress
Having reached the first anniversary following relocation to its new purpose-built laboratory on the Ca...
ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference
ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic ...
ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health
ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in ...
Proaxsis